{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:42:59Z","timestamp":1773114179808,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10549-025-07873-6","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:53:39Z","timestamp":1764946419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR\u2009+\u2009\/HER2- advanced breast cancer after CDK4\/6 inhibitor"],"prefix":"10.1007","volume":"215","author":[{"given":"Pablo","family":"Jara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ariant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianela","family":"Bringas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Echavarr\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Jerez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"L\u00f3pez-Tarruella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n","family":"M\u00e1rquez-Rodas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"del Monte-Mill\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Massarrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Ayala","family":"de la Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"20","key":"7873_CR1","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925\u20131936","journal-title":"N Engl J Med"},{"issue":"18","key":"7873_CR2","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738\u20131748","journal-title":"N Engl J Med"},{"issue":"32","key":"7873_CR3","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Tr\u00e9dan O, Bourayou N, Sohn J et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35(32):3638\u20133646","journal-title":"J Clin Oncol"},{"issue":"4","key":"7873_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"S-A Im","year":"2019","unstructured":"Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F et al (2019) Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381(4):307\u2013316","journal-title":"N Engl J Med"},{"key":"7873_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A et al (2021) Esmo clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer \u2606. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019","journal-title":"Ann Oncol"},{"issue":"9","key":"7873_CR6","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1007\/s12094-023-03203-8","volume":"25","author":"JA Garcia-Saenz","year":"2023","unstructured":"Garcia-Saenz JA, Blancas I, Echavarria I, Hinojo C, Margeli M, Moreno F et al (2023) SEOM\u2013GEICAM\u2013SOLTI clinical guidelines in advanced breast cancer (2022). Clin Transl Oncol 25(9):2665\u20132678","journal-title":"Clin Transl Oncol"},{"issue":"8","key":"7873_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","volume":"32","author":"DJ Slamon","year":"2021","unstructured":"Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S et al (2021) Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol 32(8):1015\u20131024","journal-title":"Ann Oncol"},{"issue":"20","key":"7873_CR8","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S-A, Masuda N et al (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379(20):1926\u20131936","journal-title":"N Engl J Med"},{"issue":"1","key":"7873_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge","year":"2020","unstructured":"Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X et al (2020) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy - MONARCH 2: a randomized clinical trial. JAMA Oncol 6(1):116\u2013124","journal-title":"JAMA Oncol"},{"key":"7873_CR10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407086","author":"A Bardia","year":"2024","unstructured":"Bardia A (2024) Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2407086","journal-title":"N Engl J Med"},{"issue":"1","key":"7873_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9\u201320","journal-title":"N Engl J Med"},{"issue":"10411","key":"7873_CR12","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cort\u00e9s J, Schmid P, Loirat D et al (2023) Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 402(10411):1423\u20131433","journal-title":"Lancet"},{"issue":"3","key":"7873_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S et al (2025) Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2\u2013negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol 43(3):285\u2013296","journal-title":"J Clin Oncol"},{"key":"7873_CR14","unstructured":"Chu E, De Vita VT. Cancer Chemotherapy Drug Manual. 2019."},{"issue":"9","key":"7873_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103691","volume":"9","author":"SM Tolaney","year":"2024","unstructured":"Tolaney SM, Punie K, Carey LA, Kurian AW, Ntalla I, Sjekloca N et al (2024) Real-world treatment patterns and outcomes in patients with HR+\/HER2\u2212 metastatic breast cancer treated with chemotherapy in the United States. ESMO Open 9(9):103691","journal-title":"ESMO Open"},{"issue":"SUPPL. 3","key":"7873_CR16","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.3816\/CBC.2004.s.002","volume":"4","author":"S Modi","year":"2004","unstructured":"Modi S, Seidman AD (2004) Single-agent gemcitabine in the treatment of advanced breast cancer. Clin Breast Cancer 4(SUPPL. 3):S101\u2013S106","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"7873_CR17","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.21873\/anticanres.14381","volume":"40","author":"P Heudel","year":"2020","unstructured":"Heudel P, Delaloge S, Parent D, Madranges N, Levy C, Dalenc F et al (2020) Real-world evaluation of oral vinorelbine in the treatment of metastatic breast cancer: an ESME-MBC study. Anticancer Res 40(7):3905\u20133913","journal-title":"Anticancer Res"},{"issue":"3","key":"7873_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S1470-2045(07)70041-4","volume":"8","author":"M Mart\u00edn","year":"2007","unstructured":"Mart\u00edn M, Ruiz A, Mu\u00f1oz M, Balil A, Garc\u00eda-Mata J, Calvo L et al (2007) Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8(3):219\u2013225","journal-title":"Lancet Oncol"},{"issue":"5","key":"7873_CR19","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/annonc\/mdr405","volume":"23","author":"AG Pallis","year":"2012","unstructured":"Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulias V et al (2012) A multicenter randomized phase iii trial of vinorelbine\/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Ann Oncol 23(5):1164\u20131169","journal-title":"Ann Oncol"},{"issue":"5","key":"7873_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10637-009-9285-x","volume":"28","author":"IH Park","year":"2010","unstructured":"Park IH, Ro J, Lee KS, Kim SN, Yun YH, Nam BH (2010) Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer. Invest New Drugs 28(5):659\u2013669","journal-title":"Invest New Drugs"},{"issue":"29","key":"7873_CR21","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/JCO.22.01002","volume":"40","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cortes J, Schmid P, Loirat D et al (2022) Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 40(29):3365\u20133376","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07873-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07873-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07873-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:39:06Z","timestamp":1767789546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07873-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7873"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07873-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"28"}}